Company Overview:
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc., is a biopharmaceutical company focused on developing innovative solutions for patients and healthcare providers in the fields of Critical Care and Infectious Diseases.
Our mission to deliver innovative, life-saving medicines for serious unmet medical conditions drives us every day and contributes to building a sustainable business for the long term. It also inspires our entrepreneurial culture which fosters innovation, collaboration, and a relentless commitment to the people we serve. Patients are at the center of everything we do because everyday matters. Every employee is encouraged to take initiative, explore new ideas, and turn challenges into opportunities that can potentially transform lives, especially those suffering from serious and difficult-to-treat illnesses.
Our products marketed in the U.S. include:
• GIAPREZA (angiotensin II) is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock.
• XACDURO (sulbactam for injection; durlobactam for injection) is a new treatment designed specifically to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii-calcoaceticus complex in adults.
• XERAVA (eravacycline) is a broad-spectrum antibiotic used to treat patients with complicated intra-abdominal infections (cIAI).
• ZEVTERA (ceftobiprole) is an approved advanced-generation cephalosporin antibiotic and the only FDA-approved cephalosporin specifically designed to treat adult patients with Staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis. In addition, Zevtera is approved in adult patients with acute bacterial skin and skin structure infections (ABSSSI), and adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP).
• NUZOLVENCE (zoliflodacin) for oral suspension is a first-in-class, single-dose oral antibiotic for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents 12 years of age and older weighing at least 35 kg.
Summary of Position:
The Medical Affairs Fellow will serve as an integral member of the Innoviva Specialty Therapeutics (IST) Medical Affairs team, contributing to strategic and scientific initiatives that support IST's portfolio of critical care and infectious disease therapies. As the inaugural fellow, this individual will gain broad exposure across medical strategy and operations, scientific communications, medical information, evidence generation, and cross‑functional collaboration.
The fellow will work closely with Medical Affairs leadership to support disease awareness, interpret emerging clinical data, develop scientific resources, and ensure responsible communication of scientific insights. Through partnership with the Industry Pharmacists Organization (IPhO), the fellow will additionally participate in national professional development, leadership activities, and networking within a broader community of industry fellows.
Responsibilities:
Medical Strategy & Operations
• Contribute to and help execute Medical Affairs strategic and tactical plans.
• Assist with disease awareness, therapeutic education, and evidence‑generation initiatives.
• Support preparation of advisory board materials and capture key insights to inform strategy.
Scientific Communications
• Interpret and summarize clinical trial data to support scientific messaging and Medical Affairs strategy.
• Assist with development and review of scientific slide decks, FAQs, medical response letters, and educational resources.
• Support the creation and review of abstracts, posters, and manuscripts for scientific meetings.
Medical Information
• Support the development of scientifically accurate, fair‑balanced medical information resources.
• Contribute to the creation of field‑facing scientific tools and training materials for the MSL team.
Cross‑Functional Collaboration
• Participate in optional rotations with Field Medical Affairs and other functional areas (Regulatory, Clinical Development, Commercial) as available.
• Contribute to or lead Medical Affairs projects that advance departmental objectives.
Professional Development
• Participate in IPhO National Fellows Council (NFC) initiatives, meetings, and leadership opportunities.
• Collaborate with other fellows across the IPhO network to enhance leadership, professionalism, and industry acumen.
Experience & Education:
• Doctor of Pharmacy (PharmD) degree from an ACPE‑accredited institution (to be completed by June 2026).
• Demonstrated interest in Medical Affairs, including strategy and operations, medical information, and scientific communication activities.
• Experience collaborating in fast‑paced, cross‑functional environments (industry‑related experience preferred but not required).
• Strong written and verbal communication skills with the ability to interpret complex scientific data.
• Ability to manage multiple projects with attention to detail and scientific rigor.
• Must be legally authorized to work in the United States.
• Remote work supported; proximity to Waltham, MA preferred for hybrid experience.
Skills and Abilities:
• Ability to interpret, synthesize, and communicate scientific and clinical information effectively.
• Strong organizational skills with the ability to manage multiple concurrent projects.
• Excellent interpersonal communication skills and ability to collaborate with diverse stakeholders.
• Detail oriented with commitment to scientific accuracy and compliance.
• Proactive, self-directed, and adaptable within fast-paced, evolving environments.
• Strong presentation and scientific writing abilities.
• Demonstrated professionalism, leadership potential, and willingness to learn.
Application Materials
Application Deadline: March 20, 2026
Interested candidates must submit the following materials to:
[email protected]
• Curriculum Vitae (CV)
• Three Letters of Recommendation (LORs) with Contact Information
• Unofficial College of Pharmacy Transcript
Please note Final stage candidates will be required to give a short presentation, with the topic shared in advance.
IF YOU HAVE ANY QUESTIONS PLEASE EMAIL:
[email protected]
Employment Classification Notice
Please note: If selected for this position, you will be employed by our third‑party payroll provider, which will serve as the official employer of record. While you will work on assignments for Innoviva Specialty Therapeutics, the payroll provider will manage all payroll processing, tax withholdings, and employment‑related documentation.
Equal Employment Opportunity Statement
Innoviva Specialty Therapeutics is an Equal Opportunity Employer. We provide equal employment opportunities to all employees and applicants and prohibit discrimination in all employment practices, including recruitment, hiring, compensation, benefits, promotion, training, and termination. All qualified applicants will receive consideration for employment without regard to any characteristic protected by applicable federal, state, or local law.
Work Authorization & Visa Sponsorship Policy
Innoviva Specialty Therapeutics will not provide H1-B, TN, O-1, E-3, or any other type of employment visa sponsorship for the successful applicant to this position, now or in the future. Furthermore, the successful applicant must be able to maintain valid work authorization in the United States throughout the entire appointment without IST's sponsorship for a visa.